| ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss |
ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY revenue increase, strong demand for ASCENIV, and improved gross profit margins. ADMA's financial health is robust, with $171M in cash and receivables, reduced debt costs, and a new $500M share repurchase program. |
seekingalpha.com |
2025-05-09 07:54:05 |
Czytaj oryginał (ang.) |
| ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? |
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. |
zacks.com |
2025-05-08 18:30:47 |
Czytaj oryginał (ang.) |
| ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript |
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Anthony Petrone - Mizuho Group Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon and welcome to the ADMA Biologics First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 7, 2025. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-08 03:05:02 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates |
Adma Biologics (ADMA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.08 per share a year ago. |
zacks.com |
2025-05-07 22:25:33 |
Czytaj oryginał (ang.) |
| ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update |
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1 ) of $118.6 Million), a 40% YoY Increase |
globenewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Mid-Cap Medical Stocks Outperforming the Market |
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance. |
marketbeat.com |
2025-05-06 16:50:17 |
Czytaj oryginał (ang.) |
| Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus |
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months. |
zacks.com |
2025-05-05 13:25:34 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know |
Adma Biologics (ADMA) concluded the recent trading session at $23.52, signifying a +1.07% move from its prior day's close. |
zacks.com |
2025-05-02 22:50:45 |
Czytaj oryginał (ang.) |
| Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? |
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals. |
zacks.com |
2025-05-01 18:25:33 |
Czytaj oryginał (ang.) |
| Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year? |
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year. |
zacks.com |
2025-05-01 14:46:47 |
Czytaj oryginał (ang.) |
| Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know |
Zacks.com users have recently been watching Adma Biologics (ADMA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-05-01 14:05:47 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-05-01 13:50:33 |
Czytaj oryginał (ang.) |
| These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date |
Five mid-cap high-flying stocks to buy are: ADMA, FCFS, LRN, LTH, NFG. |
zacks.com |
2025-04-30 13:26:10 |
Czytaj oryginał (ang.) |
| ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025 |
RAMSEY, N.J. and BOCA RATON, Fla. |
globenewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade |
Adma Biologics (ADMA) closed the most recent trading day at $24.11, moving -1.63% from the previous trading session. |
zacks.com |
2025-04-29 22:55:34 |
Czytaj oryginał (ang.) |
| ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process |
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity |
globenewswire.com |
2025-04-28 11:00:00 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know |
Adma Biologics (ADMA) concluded the recent trading session at $21.31, signifying a +0.38% move from its prior day's close. |
zacks.com |
2025-04-17 22:56:15 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? |
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? |
zacks.com |
2025-04-16 14:35:44 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? |
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year. |
zacks.com |
2025-04-15 14:46:04 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average |
Adma Biologics (ADMA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA crossed above the 20-day moving average, suggesting a short-term bullish trend. |
zacks.com |
2025-04-15 14:35:40 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Look Bullish on Adma Biologics (ADMA): Should You Buy? |
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? |
zacks.com |
2025-02-25 12:35:50 |
Czytaj oryginał (ang.) |
| ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 |
RAMSEY, N.J. and BOCA RATON, Fla. |
globenewswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade |
Adma Biologics (ADMA) closed the most recent trading day at $16.07, moving -0.62% from the previous trading session. |
zacks.com |
2025-02-19 20:51:27 |
Czytaj oryginał (ang.) |
| Pharma Stock Poised to Bounce Off Support |
Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January. |
schaeffersresearch.com |
2025-02-12 15:10:55 |
Czytaj oryginał (ang.) |
| ADMA Loses 8.9% in a Month: How Should You Play the Stock? |
ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain. |
zacks.com |
2025-02-07 16:46:20 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Advances But Underperforms Market: Key Facts |
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $16.92, denoting a +0.3% change from the preceding trading day. |
zacks.com |
2025-02-06 20:50:40 |
Czytaj oryginał (ang.) |
| ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add |
ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's high-titer plasma offers superior protection with minimal side effects, positioning it as a leading second-line treatment for severe PI patients. ADMA's strategic plasma collection expansion and patented methods ensure a reliable supply, supporting future growth and high-margin revenue projections exceeding $1 billion by 2030. |
seekingalpha.com |
2025-02-06 15:46:07 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note |
Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.98% move from its prior day's close. |
zacks.com |
2025-02-03 20:56:22 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors |
Adma Biologics (ADMA) closed the most recent trading day at $16.17, moving -0.12% from the previous trading session. |
zacks.com |
2025-01-28 20:56:18 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Rises Higher Than Market: Key Facts |
Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.92% move from its prior day's close. |
zacks.com |
2025-01-22 20:56:17 |
Czytaj oryginał (ang.) |
| There May Still Be Time to Get in on These 3 Trending Biotechs |
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms. |
marketbeat.com |
2025-01-20 10:15:25 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why |
The latest trading day saw Adma Biologics (ADMA) settling at $16.32, representing a -1.03% change from its previous close. |
zacks.com |
2025-01-14 20:56:20 |
Czytaj oryginał (ang.) |
| ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? |
ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain. |
zacks.com |
2025-01-10 16:45:25 |
Czytaj oryginał (ang.) |
| Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing |
Adma Biologics (ADMA) closed at $18.56 in the latest trading session, marking a +1.48% move from the prior day. |
zacks.com |
2025-01-08 21:11:43 |
Czytaj oryginał (ang.) |
| Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? |
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? |
zacks.com |
2025-01-08 12:41:45 |
Czytaj oryginał (ang.) |
| 4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow |
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025. |
zacks.com |
2024-12-24 14:51:19 |
Czytaj oryginał (ang.) |
| ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility |
Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA's Total Debt to $75 Million, a 29% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla. |
globenewswire.com |
2024-12-20 09:00:00 |
Czytaj oryginał (ang.) |
| 4 Biotech Stocks Most Wall Street Analysts Are Bullish About |
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals. |
zacks.com |
2024-12-19 16:25:23 |
Czytaj oryginał (ang.) |
| ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-13 19:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations |
LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-12 19:45:00 |
Czytaj oryginał (ang.) |
| ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-11 20:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Urges Shareholder Contributions To An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations |
LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-10 19:30:00 |
Czytaj oryginał (ang.) |
| ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip? |
ADMA Biologics has performed phenomenally in 2024. Given its strong trajectory, we recommend investors use any dip in the stock price as a buying opportunity. |
zacks.com |
2024-12-10 16:15:20 |
Czytaj oryginał (ang.) |
| ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / December 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-09 19:45:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Urges Stockholders To Join An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations |
LOS ANGELES, CA / ACCESSWIRE / December 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-08 19:15:00 |
Czytaj oryginał (ang.) |
| ADMA Biologics, Inc. Is Being Investigated For Fraud And Investors With Losses Are Invited To Reach Out To The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / December 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-07 19:30:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Urges Public Participation In An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations |
LOS ANGELES, CA / ACCESSWIRE / December 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-06 12:30:00 |
Czytaj oryginał (ang.) |
| ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / December 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-05 16:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations |
LOS ANGELES, CA / ACCESSWIRE / December 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-04 18:30:00 |
Czytaj oryginał (ang.) |
| Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect? |
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-12-04 12:56:09 |
Czytaj oryginał (ang.) |
| ADMA Biologics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Are Invited To Assist The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / December 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-03 17:15:00 |
Czytaj oryginał (ang.) |
| Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? |
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? |
zacks.com |
2024-12-02 17:21:11 |
Czytaj oryginał (ang.) |
| ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV |
ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company's key product, ASCENIV, is expected to drive significant revenue growth and improve margins, supported by a completed pediatric trial and upcoming sBLA submission. Past legal controversies about an auditor's resignation caused temporary investor concerns, but now appear resolved with KPMG's appointment as ADMA's new accounting firm. |
seekingalpha.com |
2024-12-02 10:30:30 |
Czytaj oryginał (ang.) |
| ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Invited To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / December 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-12-01 17:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Law Violations |
LOS ANGELES, CA / ACCESSWIRE / November 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market. |
accesswire.com |
2024-11-30 13:00:00 |
Czytaj oryginał (ang.) |